John Dickson | University College London Hospital (original) (raw)
Papers by John Dickson
Alzheimer's & Dementia, 2019
of brain atrophy and tau pathology. However, limited information is available for heterogeneities... more of brain atrophy and tau pathology. However, limited information is available for heterogeneities in the regional pattern of cerebral amyloid deposition in individuals with AD. We tried to identify subtypes of regional amyloid deposition in amyloid-positive cognitively impaired (CI) individuals. Methods: Total 121 amyloid-positive CI individuals consisting of mild cognitive impairment and mild AD dementia groups were included in the analysis. All participants underwent comprehensive clinical assessment, [C] PiB-PET, MRI, and blood sampling. Voxel-weighted mean PiB standard uptake value ratio (SUVR) of each ROI in cerebral gray matter and striatum defined by AAL atlas were calculated for each individual, and then z-transformed using individual’s global mean SUVR (gmSUVR) and standard deviation. Clustering analysis was performed using K-means clustering algorithm. Results: All amyloid-positive CI individuals were classified into 3 clusters after K-means clustering analysis. First, 27 individuals (22.3%) were classified as Cluster 1 (73.3 6 7.1 years; Female 85%; APOE4 positivity 63%), which demonstrated regionally higher PiB SUVR mainly in the fronto-parietal cortices, but relatively lower PiB SUVR in the medial temporal regions compared to gmSUVR. Second, 53 individuals (43.8%) fell into Cluster 2 (72.86 7.7 years; Female 60.4%; APOE4 positivity 66.0%), which showed relatively greater PiB SUVR mainly in the infero-medial temporal and occipital regions, but relatively lower PiB SUVR in the frontal regions compared to gmSUVR. Lastly, 41 individuals (33.9%) were classified to Cluster 3 (72.9 6 7.0 years; Female 58.5%; APOE4 positivity 70.7%), which showed relatively greater PiB SUVR particularly in the medial and inferior frontal cortices and striatum, but relatively lower PiB SUVR in the posterior part of brain including parieto-occipito-inferior temporal regions compared to gmSUVR. No significant differences in age and APOE4 positivity ratewere observed among clusters, but frequency of female was higher in Cluster 1 compared to other clusters. Conclusions: Our finding suggests that regional predominance of cerebral amyloid deposition may be different even in amyloid-positive individuals who already manifest cognitive impairment. Further studies to understand clinical and biological implication of these clusters are needed.
Clinical Cancer Research, 2011
Purpose: To test the hypothesis that sequential 18F-fluorodeoxyglucose-positron emission tomograp... more Purpose: To test the hypothesis that sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a correlative marker in metastatic clear cell renal cancer (mRCC), patients were treated with sunitinib. Three sequential scans were conducted to determine whether the timing of the investigation was relevant. Experimental Design: Forty-four untreated mRCC patients were enrolled into this prospective phase II study. 18F-FDG-PET/CT scans were conducted before (n = 44) and after 4 weeks (n = 43) and 16 weeks (n = 40) of sunitinib given at standard doses. The primary endpoint was to correlate FDG-PET/CT response (20% reduction in SUVmax) at 4 and 16 weeks with overall survival (OS). Results: Forty-three (98%) patients had FDG-PET/CT avid lesions at diagnosis (median SUVmax = 6.8, range: <2.5–18.4). In multivariate analysis, a high SUVmax and an increased number of PET-positive lesions correlated with shorter OS [HR: 3.30 (95% CI: 1.36–8.45) and 3.67...
![Research paper thumbnail of Operationalising the Centiloid Scale for [18F]florbetapir PET Studies on PET/MR](https://attachments.academia-assets.com/98083905/thumbnails/1.jpg)
](ABSTRACTPurposeThe Centiloid scale provides a systematic means of harmonising amyloid-β PET measu... more ABSTRACTPurposeThe Centiloid scale provides a systematic means of harmonising amyloid-β PET measures across different acquisition and processing methodologies. This work explores the Centiloid transformation of [18F]florbetapir PET data acquired on a combined PET/MR scanner and processed with methods that differ from the standard Centiloid pipeline.MethodsThe Standard PiB and Florbetapir Calibration datasets were processed using a standardised uptake value ratio (SUVR) pipeline with MRI parcellations from the Geodesic Information Flow (GIF) algorithm in native PET space. We generated SUVRs using whole cerebellum (GIF_WCSUVR) and eroded white matter (GIF_WMSUVR) reference regions, with and without partial volume correction (PVC). Linear regression was used to calibrate these processing pipelines to the standard Centiloid approach. We then applied the resulting transformation to 432 florbetapir scans from the Insight 46 study of mostly cognitively normal individuals aged ∼70 years, an...
The Journal of Nuclear Medicine, 2016
Alzheimer's & Dementia, 2019
between EMCIs and LMCIs in cognitive decline rate or tracer uptake, thus the subjects were combin... more between EMCIs and LMCIs in cognitive decline rate or tracer uptake, thus the subjects were combined for further analysis. Chisquare test found no difference between A-T-, A+T-, A-T+, A+T+ groups (Fisher exact test P1⁄40.68). Fast decliners had significant higher tau load in temporal lobe (P1⁄40.16), hippocampus (P1⁄40.02), para-hippocampal gyrus (P<0.01), while no significant difference of amyloid load or glucose metabolic rate (MRGlc) was observed. Significant correlation was found between cognitive decline rate and tau deposition in medial temporal lobe (P1⁄40.02) and parahippocampal gyrus (P1⁄40.01) but not amyloid load, rCMRGlc or initial ADAS score. Logistic regression found only parahippocampal gyrus tau load (P<0.01) was predictive for fast decliners. Conclusions: Tau load is identified as the most important predictor for short-term cognitive decline among MCI patients regardless of amyloid load. Interestingly, baseline glucose metabolic rate or initial ADAS score did not predict the future deterioration in MCI subjects.
European Journal of Hybrid Imaging, 2019
Routinely, there is a visual basis to nuclear medicine reporting: a reporter subjectively places ... more Routinely, there is a visual basis to nuclear medicine reporting: a reporter subjectively places a patient's condition into one of multiple discrete classes based on what they see. The addition of a quantitative result, such as a standardised uptake value (SUV), would provide a numerical insight into the nature of uptake, delivering greater objectivity, and perhaps improved patient management. For bone scintigraphy in particular quantification could increase the accuracy of diagnosis by helping to differentiate normal from abnormal uptake. Access to quantitative data might also enhance our ability to characterise lesions, stratify and monitor patients' conditions, and perform reliable dosimetry for radionuclide therapies. But is there enough evidence to suggest that we, as a community, should be making more effort to implement quantitative bone SPECT in routine clinical practice? We carried out multiple queries through the PubMed search engine to facilitate a crosssectional review of the current status of bone SPECT quantification. Highly cited papers were assessed in more focus to scrutinise their conclusions. An increasing number of authors are reporting findings in terms of metrics such as SUV max. Although interest in the field in general remains high, the rate of clinical implementation of quantitative bone SPECT remains slow and there is a significant amount of validation required before we get carried away.
European Journal of Nuclear Medicine and Molecular Imaging, 2011
Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interv... more Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interventions. Imaging components in such trials are becoming increasingly common; however, without sufficient control measures the usefulness of these data can be compromised. This paper describes a framework for performing high-quality multi-centre trials with single photon emission computed tomography (SPECT), using a pan-European initiative to acquire a normal control dopamine transporter brain scan database as an example. A framework to produce high-quality and consistent SPECT imaging data was based on three key areas: quality assurance, the imaging protocol and system characterisation. Quality assurance was important to ensure that the quality of the equipment and local techniques was good and consistently high; system characterisation helped understand and where possible match the performance of the systems involved, whereas the imaging protocol was designed to allow a degree of flexibility to best match the characteristics of each imaging device. A total of 24 cameras on 15 sites from 8 different manufacturers were evaluated for inclusion in our multi-centre initiative. All results matched the required level of specification and each had their performance characterised. Differences in performance were found between different system types and cameras of the same type. Imaging protocols for each site were modified to match their individual characteristics to produce comparable high-quality SPECT images. A framework has been designed to produce high-quality data for multi-centre SPECT studies. This framework has been successfully applied to a pan-European initiative to acquire a healthy control dopamine transporter image database.
In European Journal of Nuclear Medicine and Molecular Imaging, Oct 1, 2012
Diagnostics
The application of absolute quantification in SPECT/CT has seen increased interest in the context... more The application of absolute quantification in SPECT/CT has seen increased interest in the context of radionuclide therapies where patient-specific dosimetry is a requirement within the European Union (EU) legislation. However, the translation of this technique to diagnostic nuclear medicine outside this setting is rather slow. Clinical research has, in some examples, already shown an association between imaging metrics and clinical diagnosis, but the applications, in general, lack proper validation because of the absence of a ground truth measurement. Meanwhile, additive manufacturing or 3D printing has seen rapid improvements, increasing its uptake in medical imaging. Three-dimensional printed phantoms have already made a significant impact on quantitative imaging, a trend that is likely to increase in the future. In this review, we summarize the data of recent literature to underpin our premise that the validation of diagnostic applications in nuclear medicine using application-sp...
BMJ Open, 2021
IntroductionParkinson’s disease (PD) is a common neurodegenerative disorder with substantial morb... more IntroductionParkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year. The aim of this multicentre UK trial is to confirm whether these previous positive results are maintained in a larger number of participants over 2 years and if effects accumulate with prolonged drug exposure.Methods and analysisThis is a phase 3, multicentre, double-blind, randomised, placebo-controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate PD. Treatment duration is 96 weeks. Randomisation is 1:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96 weeks.The primary outcome is the comparison of Movement Disorders Society Unified Parkinson’s Disease Rating Scale part 3 motor subscore in the practical...
Stem Cell Research & Therapy, 2020
Background MSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived... more Background MSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived MSCs genetically modified to express the anti-cancer protein TRAIL. Though cell-based therapies are typically designed with a target tissue in mind, delivery is rarely assessed due to a lack of translatable non-invasive imaging approaches. In this preclinical study, we demonstrate 89Zr-oxine labelling and PET-CT imaging as a potential clinical solution for non-invasively tracking MSCTRAIL biodistribution. Future implementation of this technique should improve our understanding of MSCTRAIL during its evaluation as a therapy for metastatic lung adenocarcinoma. Methods MSCTRAIL were radiolabelled with 89Zr-oxine and assayed for viability, phenotype, and therapeutic efficacy post-labelling. PET-CT imaging of 89Zr-oxine-labelled MSCTRAIL was performed in a mouse model of lung cancer following intravenous injection, and biodistribution was confirmed ex vivo. Results MSCTRAIL retained the ther...
European Radiology, 2008
The aim of this study is to quantify myocardial perfusion during coronary CT angiography using da... more The aim of this study is to quantify myocardial perfusion during coronary CT angiography using data from a modified timing test-bolus acquisition. Institutional review board approval and informed consent were obtained. Nineteen patients with suspected coronary artery disease underwent combined coronary CT angiography and cardiac (82)Rubidium-PET perfusion. Prior to the CT angiogram a retrospectively ECG-gated dynamic test bolus was obtained following 25 mls of IV contrast medium injected at 5 ml/s. Images were acquired every 1.5 s for 30 s using 4 x 1.25-mm slices at 120 kV, 35 mAs. Regions of interest were drawn to delineate the myocardium and aorta on the resulting transaxial images. Time density curves were created and perfusion calculated using two simple approaches: maximum-slope method and peak method. In patients with normal PET myocardial perfusion, the mean (SD) resting myocardial perfusion estimated by CT using the maximum-slope method was 0.89 (+/-0.27) ml/min/g and 0.93 (+/-0.21) ml/min/g at end-systole and end-diastole, respectively, and 0.69 (+/-0.11) ml/min/g and 0.79 (+/-0.19) at end-systole and end-diastole, respectively, for the peak method. Thus quantification of myocardial perfusion from a routine coronary CT angiography test bolus is possible. CT-derived myocardial perfusion values are consistent with published values derived from other techniques.
... Dickson, JC and Prakash, VV and Kayani, I and Bomanji, JB and Waddington, WA and Ell, PJ and ... more ... Dickson, JC and Prakash, VV and Kayani, I and Bomanji, JB and Waddington, WA and Ell, PJ and Hutton, BF (2007) Evaluation of imaging times used in oncological PETCT. ... Dates: 2007. Additional information: Invalid ISBN vara, Italy read from Web of Science. ...
Nuclear Medicine Communications, 2007
Alzheimer's & Dementia, 2019
of brain atrophy and tau pathology. However, limited information is available for heterogeneities... more of brain atrophy and tau pathology. However, limited information is available for heterogeneities in the regional pattern of cerebral amyloid deposition in individuals with AD. We tried to identify subtypes of regional amyloid deposition in amyloid-positive cognitively impaired (CI) individuals. Methods: Total 121 amyloid-positive CI individuals consisting of mild cognitive impairment and mild AD dementia groups were included in the analysis. All participants underwent comprehensive clinical assessment, [C] PiB-PET, MRI, and blood sampling. Voxel-weighted mean PiB standard uptake value ratio (SUVR) of each ROI in cerebral gray matter and striatum defined by AAL atlas were calculated for each individual, and then z-transformed using individual’s global mean SUVR (gmSUVR) and standard deviation. Clustering analysis was performed using K-means clustering algorithm. Results: All amyloid-positive CI individuals were classified into 3 clusters after K-means clustering analysis. First, 27 individuals (22.3%) were classified as Cluster 1 (73.3 6 7.1 years; Female 85%; APOE4 positivity 63%), which demonstrated regionally higher PiB SUVR mainly in the fronto-parietal cortices, but relatively lower PiB SUVR in the medial temporal regions compared to gmSUVR. Second, 53 individuals (43.8%) fell into Cluster 2 (72.86 7.7 years; Female 60.4%; APOE4 positivity 66.0%), which showed relatively greater PiB SUVR mainly in the infero-medial temporal and occipital regions, but relatively lower PiB SUVR in the frontal regions compared to gmSUVR. Lastly, 41 individuals (33.9%) were classified to Cluster 3 (72.9 6 7.0 years; Female 58.5%; APOE4 positivity 70.7%), which showed relatively greater PiB SUVR particularly in the medial and inferior frontal cortices and striatum, but relatively lower PiB SUVR in the posterior part of brain including parieto-occipito-inferior temporal regions compared to gmSUVR. No significant differences in age and APOE4 positivity ratewere observed among clusters, but frequency of female was higher in Cluster 1 compared to other clusters. Conclusions: Our finding suggests that regional predominance of cerebral amyloid deposition may be different even in amyloid-positive individuals who already manifest cognitive impairment. Further studies to understand clinical and biological implication of these clusters are needed.
Clinical Cancer Research, 2011
Purpose: To test the hypothesis that sequential 18F-fluorodeoxyglucose-positron emission tomograp... more Purpose: To test the hypothesis that sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a correlative marker in metastatic clear cell renal cancer (mRCC), patients were treated with sunitinib. Three sequential scans were conducted to determine whether the timing of the investigation was relevant. Experimental Design: Forty-four untreated mRCC patients were enrolled into this prospective phase II study. 18F-FDG-PET/CT scans were conducted before (n = 44) and after 4 weeks (n = 43) and 16 weeks (n = 40) of sunitinib given at standard doses. The primary endpoint was to correlate FDG-PET/CT response (20% reduction in SUVmax) at 4 and 16 weeks with overall survival (OS). Results: Forty-three (98%) patients had FDG-PET/CT avid lesions at diagnosis (median SUVmax = 6.8, range: <2.5–18.4). In multivariate analysis, a high SUVmax and an increased number of PET-positive lesions correlated with shorter OS [HR: 3.30 (95% CI: 1.36–8.45) and 3.67...
ABSTRACTPurposeThe Centiloid scale provides a systematic means of harmonising amyloid-β PET measu... more ABSTRACTPurposeThe Centiloid scale provides a systematic means of harmonising amyloid-β PET measures across different acquisition and processing methodologies. This work explores the Centiloid transformation of [18F]florbetapir PET data acquired on a combined PET/MR scanner and processed with methods that differ from the standard Centiloid pipeline.MethodsThe Standard PiB and Florbetapir Calibration datasets were processed using a standardised uptake value ratio (SUVR) pipeline with MRI parcellations from the Geodesic Information Flow (GIF) algorithm in native PET space. We generated SUVRs using whole cerebellum (GIF_WCSUVR) and eroded white matter (GIF_WMSUVR) reference regions, with and without partial volume correction (PVC). Linear regression was used to calibrate these processing pipelines to the standard Centiloid approach. We then applied the resulting transformation to 432 florbetapir scans from the Insight 46 study of mostly cognitively normal individuals aged ∼70 years, an...
The Journal of Nuclear Medicine, 2016
Alzheimer's & Dementia, 2019
between EMCIs and LMCIs in cognitive decline rate or tracer uptake, thus the subjects were combin... more between EMCIs and LMCIs in cognitive decline rate or tracer uptake, thus the subjects were combined for further analysis. Chisquare test found no difference between A-T-, A+T-, A-T+, A+T+ groups (Fisher exact test P1⁄40.68). Fast decliners had significant higher tau load in temporal lobe (P1⁄40.16), hippocampus (P1⁄40.02), para-hippocampal gyrus (P<0.01), while no significant difference of amyloid load or glucose metabolic rate (MRGlc) was observed. Significant correlation was found between cognitive decline rate and tau deposition in medial temporal lobe (P1⁄40.02) and parahippocampal gyrus (P1⁄40.01) but not amyloid load, rCMRGlc or initial ADAS score. Logistic regression found only parahippocampal gyrus tau load (P<0.01) was predictive for fast decliners. Conclusions: Tau load is identified as the most important predictor for short-term cognitive decline among MCI patients regardless of amyloid load. Interestingly, baseline glucose metabolic rate or initial ADAS score did not predict the future deterioration in MCI subjects.
European Journal of Hybrid Imaging, 2019
Routinely, there is a visual basis to nuclear medicine reporting: a reporter subjectively places ... more Routinely, there is a visual basis to nuclear medicine reporting: a reporter subjectively places a patient's condition into one of multiple discrete classes based on what they see. The addition of a quantitative result, such as a standardised uptake value (SUV), would provide a numerical insight into the nature of uptake, delivering greater objectivity, and perhaps improved patient management. For bone scintigraphy in particular quantification could increase the accuracy of diagnosis by helping to differentiate normal from abnormal uptake. Access to quantitative data might also enhance our ability to characterise lesions, stratify and monitor patients' conditions, and perform reliable dosimetry for radionuclide therapies. But is there enough evidence to suggest that we, as a community, should be making more effort to implement quantitative bone SPECT in routine clinical practice? We carried out multiple queries through the PubMed search engine to facilitate a crosssectional review of the current status of bone SPECT quantification. Highly cited papers were assessed in more focus to scrutinise their conclusions. An increasing number of authors are reporting findings in terms of metrics such as SUV max. Although interest in the field in general remains high, the rate of clinical implementation of quantitative bone SPECT remains slow and there is a significant amount of validation required before we get carried away.
European Journal of Nuclear Medicine and Molecular Imaging, 2011
Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interv... more Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interventions. Imaging components in such trials are becoming increasingly common; however, without sufficient control measures the usefulness of these data can be compromised. This paper describes a framework for performing high-quality multi-centre trials with single photon emission computed tomography (SPECT), using a pan-European initiative to acquire a normal control dopamine transporter brain scan database as an example. A framework to produce high-quality and consistent SPECT imaging data was based on three key areas: quality assurance, the imaging protocol and system characterisation. Quality assurance was important to ensure that the quality of the equipment and local techniques was good and consistently high; system characterisation helped understand and where possible match the performance of the systems involved, whereas the imaging protocol was designed to allow a degree of flexibility to best match the characteristics of each imaging device. A total of 24 cameras on 15 sites from 8 different manufacturers were evaluated for inclusion in our multi-centre initiative. All results matched the required level of specification and each had their performance characterised. Differences in performance were found between different system types and cameras of the same type. Imaging protocols for each site were modified to match their individual characteristics to produce comparable high-quality SPECT images. A framework has been designed to produce high-quality data for multi-centre SPECT studies. This framework has been successfully applied to a pan-European initiative to acquire a healthy control dopamine transporter image database.
In European Journal of Nuclear Medicine and Molecular Imaging, Oct 1, 2012
Diagnostics
The application of absolute quantification in SPECT/CT has seen increased interest in the context... more The application of absolute quantification in SPECT/CT has seen increased interest in the context of radionuclide therapies where patient-specific dosimetry is a requirement within the European Union (EU) legislation. However, the translation of this technique to diagnostic nuclear medicine outside this setting is rather slow. Clinical research has, in some examples, already shown an association between imaging metrics and clinical diagnosis, but the applications, in general, lack proper validation because of the absence of a ground truth measurement. Meanwhile, additive manufacturing or 3D printing has seen rapid improvements, increasing its uptake in medical imaging. Three-dimensional printed phantoms have already made a significant impact on quantitative imaging, a trend that is likely to increase in the future. In this review, we summarize the data of recent literature to underpin our premise that the validation of diagnostic applications in nuclear medicine using application-sp...
BMJ Open, 2021
IntroductionParkinson’s disease (PD) is a common neurodegenerative disorder with substantial morb... more IntroductionParkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year. The aim of this multicentre UK trial is to confirm whether these previous positive results are maintained in a larger number of participants over 2 years and if effects accumulate with prolonged drug exposure.Methods and analysisThis is a phase 3, multicentre, double-blind, randomised, placebo-controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate PD. Treatment duration is 96 weeks. Randomisation is 1:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96 weeks.The primary outcome is the comparison of Movement Disorders Society Unified Parkinson’s Disease Rating Scale part 3 motor subscore in the practical...
Stem Cell Research & Therapy, 2020
Background MSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived... more Background MSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived MSCs genetically modified to express the anti-cancer protein TRAIL. Though cell-based therapies are typically designed with a target tissue in mind, delivery is rarely assessed due to a lack of translatable non-invasive imaging approaches. In this preclinical study, we demonstrate 89Zr-oxine labelling and PET-CT imaging as a potential clinical solution for non-invasively tracking MSCTRAIL biodistribution. Future implementation of this technique should improve our understanding of MSCTRAIL during its evaluation as a therapy for metastatic lung adenocarcinoma. Methods MSCTRAIL were radiolabelled with 89Zr-oxine and assayed for viability, phenotype, and therapeutic efficacy post-labelling. PET-CT imaging of 89Zr-oxine-labelled MSCTRAIL was performed in a mouse model of lung cancer following intravenous injection, and biodistribution was confirmed ex vivo. Results MSCTRAIL retained the ther...
European Radiology, 2008
The aim of this study is to quantify myocardial perfusion during coronary CT angiography using da... more The aim of this study is to quantify myocardial perfusion during coronary CT angiography using data from a modified timing test-bolus acquisition. Institutional review board approval and informed consent were obtained. Nineteen patients with suspected coronary artery disease underwent combined coronary CT angiography and cardiac (82)Rubidium-PET perfusion. Prior to the CT angiogram a retrospectively ECG-gated dynamic test bolus was obtained following 25 mls of IV contrast medium injected at 5 ml/s. Images were acquired every 1.5 s for 30 s using 4 x 1.25-mm slices at 120 kV, 35 mAs. Regions of interest were drawn to delineate the myocardium and aorta on the resulting transaxial images. Time density curves were created and perfusion calculated using two simple approaches: maximum-slope method and peak method. In patients with normal PET myocardial perfusion, the mean (SD) resting myocardial perfusion estimated by CT using the maximum-slope method was 0.89 (+/-0.27) ml/min/g and 0.93 (+/-0.21) ml/min/g at end-systole and end-diastole, respectively, and 0.69 (+/-0.11) ml/min/g and 0.79 (+/-0.19) at end-systole and end-diastole, respectively, for the peak method. Thus quantification of myocardial perfusion from a routine coronary CT angiography test bolus is possible. CT-derived myocardial perfusion values are consistent with published values derived from other techniques.
... Dickson, JC and Prakash, VV and Kayani, I and Bomanji, JB and Waddington, WA and Ell, PJ and ... more ... Dickson, JC and Prakash, VV and Kayani, I and Bomanji, JB and Waddington, WA and Ell, PJ and Hutton, BF (2007) Evaluation of imaging times used in oncological PETCT. ... Dates: 2007. Additional information: Invalid ISBN vara, Italy read from Web of Science. ...
Nuclear Medicine Communications, 2007